1-3 of 3
Lisa Argnani
Close
Sort by
Journal Articles

Single-agent rituximab is an effective salvage therapy in pretreated patients with hairy cell leukemia

Clinical Trials & Observations
Alessandro Broccoli, Lisa Argnani, Laura Nanni, Vittorio Stefoni, Cinzia Pellegrini, Beatrice Casadei, Gabriele Gugliotta, Matteo Carella, Paolo Elia Coppola, Gianmarco Bagnato, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6762–6766.
https://doi.org/10.1182/bloodadvances.2023010742
Published: 2023
Includes: Supplemental data
Journal Articles

A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia

Clinical Trials & Observations
Alessandro Broccoli, Lisa Argnani, Matthew Cross, Agnieszka Janus, Elsa Maitre, Xavier Troussard, Tadeusz Robak, Claire Dearden, Monica Else, Daniel Catovsky, Pier Luigi Zinzani
Journal: Blood Advances
Blood Adv (2022) 6 (14): 4224–4227.
https://doi.org/10.1182/bloodadvances.2022007854
Published: 2022
Includes: Supplemental data
Journal Articles

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma

Clinical Trials & Observations
Juan Pablo Alderuccio, Luca Arcaini, Marcus P. Watkins, Anne W. Beaven, Geoffrey Shouse, Narendranath Epperla, Michele Spina, Alexandra Stefanovic, Jose Sandoval-Sus, Pallawi Torka, Ash B. Alpert, Adam J. Olszewski, Seo-Hyun Kim, Brian Hess, Sameh Gaballa, Sabarish Ayyappan, Jorge J. Castillo, Lisa Argnani, Timothy J. Voorhees, Raya Saba, Sayan Mullick Chowdhury, Fernando Vargas, Isildinha M. Reis, Deukwoo Kwon, Jonathan S. Alexander, Wei Zhao, Dali Edwards, Peter Martin, Emanuele Cencini, Manali Kamdar, Brian K. Link, Constantine N. Logothetis, Alex F. Herrera, Jonathan W. Friedberg, Brad S. Kahl, Stefano Luminari, Pier Luigi Zinzani, Izidore S. Lossos
Journal: Blood Advances
Blood Adv (2022) 6 (7): 2035–2044.
https://doi.org/10.1182/bloodadvances.2021006844
Published: 2022